Presentation HER2高発現胃がん腹膜播種に対するα線放出核種211Atを用いた放射免疫療法

李, 惠子  ,  諸越, 幸恵  ,  長谷川, 純崇

Peritoneal metastasis of gastric cancer (PMGC) has extremely poor prognosis, however, there is no effective therapeutics has been established. About 20% of GC is reported as HER2-overexpressed (HER2+), and trastuzumab, a humanized anti-HER2 monoclonal antibody, has been used for the treatment for HER2+ PMGC. Radioimmunotherapy (RIT) has huge advantages in targeting metastatic cancer and the application of alpha-emitter into RIT is getting higher attention. Astatine 211 (<SUP>211</SUP>At) is one of the useful alpha-emitter. In this study, we investigated the cell cytotoxicity and therapeutic efficacy of RIT with <SUP>211</SUP>At-trastuzumab against of HER2+ PMGC both in vitro and in vivo. We will discuss the possibility of alpha-RIT with <SUP>211</SUP>At-trastuzumab as a new effective therapeutics for HER2+ PMGC.

Number of accesses :  

Other information